Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;sulfuric acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

44 API Suppliers, 25 USDMF, 7 CEP/COS, 10 EU WC, 2 KDMF, 18 NDC API, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

75 FDF Dossiers, 42 FDA Orange Book, 14 Europe, 11 Canada, 2 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 8 DKSH, 5 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

34 Fillers, Diluents & Binders, 22 Disintegrants & Superdisintegrants, 21 Thickeners and Stabilizers, 18 Granulation, 16 Lubricants & Glidants, 15 Direct Compression, 13 Coating Systems & Additives, 8 Film Formers & Plasticizers, 8 Empty Capsules, 8 Emulsifying Agents, 8 Co-Processed Excipients, 7 Taste Masking, 7 Topical, 4 Solubilizers, 4 Controlled & Modified Release, 4 Chewable & Orodispersible Aids, 4 Parenteral, 3 Surfactant & Foaming Agents, 3 Coloring Agents, 2 Rheology Modifiers, 1 API Stability Enhancers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 10 News #PharmaBuzz

GLOBAL SALES INFORMATION

9 US Medicaid Prescriptions, 5 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Granules India Limited	India	GRANULES INDIA LIMITED Hyderabad IN	CEP 2020-279 - Rev 01	Atazanavir sulfate	2024-06-10	Valid	Chemical		2898
29/11/2025	Aurobindo Pharma Limited	India	APITORIA PHARMA PRIVATE LIMITED Hyderabad IN	CEP 2020-031 - Rev 01	Atazanavir sulfate	2023-12-06	Valid	Chemical		2898

Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;sulfuric Acid

methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;sulfuric acid

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

44 API Suppliers

25 USDMF

7 CEP/COS

10 EU WC

2 KDMF

18 NDC API

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

75 FDF Dossiers

42 FDA Orange Book

14 Europe

11 Canada

2 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG

CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 200MG BASE

CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

1 SPI Pharma

8 DKSH

5 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Pfanstiehl

2 Kirsch Pharma

4 ACG Worldwide

1 Actylis

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 BASF

6 DFE Pharma

1 Finar

6 Gangwal Chemicals

1 Ideal Cures

2 Ingredion Pharma Solutions

10 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

2 Nitika Pharmaceutical Specialities

2 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qualicaps

14 Roquette

3 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

4 Silverline Chemicals

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

34 Fillers, Diluents & Binders

22 Disintegrants & Superdisintegrants

21 Thickeners and Stabilizers

18 Granulation

16 Lubricants & Glidants

15 Direct Compression

13 Coating Systems & Additives

8 Film Formers & Plasticizers

8 Empty Capsules

8 Emulsifying Agents

8 Co-Processed Excipients

7 Taste Masking

7 Topical

4 Solubilizers

4 Controlled & Modified Release

4 Chewable & Orodispersible Aids

CAPSULE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons